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Dear editors: 
 
Although attainment of sustained virological response (SVR) reduces the incidence of hepatocellular 
carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection, increased risk of HCC 
remains [1]. In the largest series to date, risk factors associated with persistent HCC risk after SVR 
achievement included increasing age, presence of cirrhosis and diabetes [2]. It is striking, however, that 
35% of HCC cases in that cohort arose within the first year following SVR attainment and the overall 
median time between SVR and HCC detection was 1.66 years [2]. This observation raises the possibility 
that HCC was present prior to SVR attainment. 
 
We have been conducting a prospective observational study designed to investigate the effect of Direct 
Acting Anti-viral (DAA) therapy on the liver of HCV patients using a published non-contrast MRI protocol 
[3]. Seven (of 41) patients in our study were diagnosed with HCC subsequent to onset of DAA therapy 
(6 de novo and 1 recurrence). In each case there was, serendipitously obtained, radiological evidence 
of the presence of HCC before onset of DAA therapy. Here we describe these cases of HCC, 6 of which 
would have fulfilled criteria for development after SVR according to classification criteria [4, 5].  
 
Six (of seven) patients were male, median age 55 (range 50 – 69), BMI 25.9 (23.4 - 32), MELD 9 (7-
15). Six (of seven) had decompensated cirrhosis, 5 had HCV genotype 3, 2 genotype 1a. All patients 
had a normal pre-treatment α-fetoprotein, median 9 ng/mL (7 – 15). 4/7 achieved SVR, one died during 
treatment and two underwent transplant. Post-hoc processing of pre-treatment research MRI scans 
showed 6/7 lesions were detectable 36 - 511 days before clinical diagnosis of HCC (Figure 1). No pre-
treatment lesion was identified in Patient 7, but a lesion was detectable on the post-treatment research 
scan 106 days before clinical diagnosis.   
 
Only one patient (Patient 3) had recurrent HCC, with radio-frequency ablation 3 years prior to this study. 
The other six were de novo HCC. 4 HCCs were detected by routine abdominal ultrasound surveillance 
14 days following initiation of DAA treatment (Patient 6), or 199 - 389 days post completion of DAA 
treatment (patients 2, 5 and 7). Of the remaining three patients Patient 1 presented with a raised 
screening alpha-fetoprotein (49 days post DAA treatment completion), Patient 3 presented with acute 
decompensation (ascites) 50 days after starting DAAs, and the HCC in Patient 4 was detected on 
routine imaging at transplant work-up (34 days post DAA treatment completion).  
 
Radiological reports and multi-disciplinary team notes were retrieved. 5/7 patients had clinical MRI 
scans to confirm the diagnosis of HCC. These clinical scans were anonymised, randomised and the 
DICOM files exported. Clinical MR images then underwent identical post-hoc processing to the research 
scans and were reconstructed into 3D images by researchers blinded to the patients’ identity. An 
independent researcher was tasked with matching the clinical and research scans – and succeeded in 
doing so for all 5 patients (Figure 1).  All lesions identified on the DIXON scans were in the same 
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segment as the HCCs that were subsequently diagnosed. The matching of HCC lesions between the 
clinical “diagnostic” scans and preceding research DIXON MRI scans, both in terms of anatomical 
location and similarity in size, is highly suggestive that the HCCs were present but not clinically evident.  
 
Three patients had a screening ultrasound that was reported as normal (9-367 days) after the research 
MRI scan, analysed post hoc, had a demonstrated a lesion. 5/7 cases of HCC had a normal surveillance 
ultrasound in the six month period prior to DAA therapy (median interval 36 days). This is consistent 
with the known relative insensitivity of ultrasound in the detection of tumours [6, 7]. 
 
Our data unequivocally demonstrate that lesions which ultimately co-localise with subsequently formally 
diagnosed HCCs exist before DAA therapy is started, and support the argument that the increased 
prevalence of HCC following DAA treatment is because DAA-treated patients have more advanced liver 
disease [1, 2] rather than the risk attributable to DAA therapy [8].  
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Figure 1: Post-hoc image analysis could retrospectively identify lesions (coloured pink) within the liver 
(blue) on the water-only DIXON MRI scans of all 7 patients (1-7) who developed HCC before the 
clinical diagnosis was made. Using in-house software (MATLAB, The Mathworks Inc., Natick, MA), 
the DIXON water-only images of the pre- and post-MRI scan sessions were thresholded at 80% of the 
mean liver intensity to automatically segment the lesions from the liver tissue. These images were 
then 3D rendered. 
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